FDA clears Zyn nicotine pouches as lower-risk alternative to smoking
The FDA said it would allow Philip Morris to market Zyn nicotine pouches as a lower-risk alternative to cigarettes, approving 20 variants with claims that using Zyn reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. Regulators see potential population-health benefits, while scientists caution about risks to new users and youth. Philip Morris has been expanding Zyn sales and has lobbied for clearer, faster FDA approvals.